Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Research and pharmaceuticals: EU ‘pharming’ solutions to major diseases


A team of European researchers plans to perfect techniques for producing antibodies and vaccines, obtained from plants, to prevent and treat major human diseases, such as AIDS, rabies and TB. The idea is to use genetically modified (GM) crops eventually to produce plant-based pharmaceuticals. Pharma-Planta is a consortium of eleven European countries and South Africa which, thanks to €12 million in EU funding, plans to produce vaccines and other treatments for major diseases, such as HIV/AIDS, rabies and tuberculosis. The project, led by the Fraunhofer Institute for molecular biology and ecology in Aachen (Germany), with scientific co-ordination by St George’s Hospital Medical School in London (UK), hopes to start clinical trials by the end of the funding period in 2009.

“The development of new drugs derived from plants, made possible thanks to recent advances in plant genetics, can benefit from cross-disciplinary collaboration at European level” commented Research Commissioner Philippe Busquin about this EU project. “The consortium of 39 research teams from across Europe and South Africa will combine expertise across disciplines, such as immunology and plant sciences, to offer real promise in this complex high-technology area.”


Plant-based pharmaceutical production, or ‘pharming’, offers several advantages over traditional approaches. The current methods used to generate these types of treatments involve culturing cells or microorganisms, such as bacteria which are labour intensive, expensive and often only produce relatively small amounts of pharmaceuticals. But plants are inexpensive to grow and if “engineered” to contain a gene for a pharmaceutical product, they could produce large quantities of drugs or vaccines at low cost.

First concrete applications

The first product that might come out of the EU integrated project, possibly grown in maize, is likely to be an antibody that neutralises the AIDS virus. This could be incorporated for example, in a simple-to-apply microbicidal cream and used for blocking HIV transmission. Next would probably be a monoclonal antibody against rabies – still a major killer in the developing world and responsible for up to 70,000 deaths a year – which could be used after contracting the virus.

Checks and balances

The production of pharmaceuticals in GM plants would be subject to control by multiple regulatory agencies, including those governing the use of genetically modified organisms and those governing the production of drugs. Part of Pharma-Planta’s remit will also be to identify secure methods and places for production.

Although the consortium has yet to decide which plants to use, likely candidates include maize, tobacco and tomatoes. Plants possessing the desired proteins for producing so-called ‘immunotherapeutic bio-molecules’ – which can be found in high enough quantities in the seeds and harvested easily – will be given preference.

Fabio Fabbi | European Union
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>